NCT04300049 (Glucagon) is a EARLY_PHASE1 clinical trial of Glucagon Infusion in Insulin Sensitivity, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT04300049?

NCT04300049 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT04300049?

Interventions in NCT04300049: Glucagon Infusion, Saline.

What condition does NCT04300049 study?

NCT04300049 studies Insulin Sensitivity.

Is NCT04300049 still recruiting?

NCT04300049 is currently completed. Last updated 21 October 2024.

Last reviewed 2024-10-21 · How we verify

NCT04300049: Glucagon

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism

Completed EARLY_PHASE1 Last updated 21 October 2024

What this trial tests

EARLY_PHASE1 trial testing Glucagon Infusion in Insulin Sensitivity in 10 participants. Completed in 15 November 2023.

Timeline

5 February 2018

Primary endpoint
15 November 2023

15 November 2023

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	5 February 2018
Primary completion	15 November 2023
Estimated completion	15 November 2023
Sites	2 locations across United States

Drugs / interventions tested

Glucagon Infusion — full drug profile →
Saline

Conditions studied

Insulin Sensitivity — all drugs for Insulin Sensitivity →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

Adults 18 to 50, any sex, with Insulin Sensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose/Objectives: To investigate the effect of hyperglucagonemia on insulin action, particularly on adipose tissue. Research Design/Plan: Normal glucose tolerant subjects will be studied. Study subjects will receive a continuous glucagon infusion for 12 hours. Following glucagon infusion, subjects will receive prime-continuous tracer infusions for additional 4 hours to measure adipocyte metabolism. Within 6-8 weeks, subjects will return for a repeat study with normal saline as a control group. Methods: All subjects will have an oral glucose tolerance test prior to participation to confirm they are normal glucose tolerant. Subjects will be admitted to the CRC at 4 PM and will receive a continuous glucagon for 12 hours. At 6 AM on the following morning, subjects will receive prime-continuous tracer infusions of the following for 4 hours (14C-glycerol, 3-3H glucose, and D2O). At 10 AM continuous indirect calorimetry will be performed to determine rates of energy expenditure and glucose/lipid oxidation for 40 minutes. At 6 AM a surgical biopsy of abdominal adipose tissue will be performed for measurement of adipocyte metabolism. At 8 AM, the study team will infuse insulin/glucose to test for insulin sensitivity. Clinical Relevance: The results of this study will help the study team to further understand the pathophysiology of metabolic disturbances that is induced by hyperglucagonemia in type 2 diabetes patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Insulin Sensitivity

Currently open trials in the same condition.

NCT07247734 — The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation · Phase 2 · recruiting
NCT06939959 — Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease. · Phase 4 · recruiting
NCT06649981 — Aging Resilience Through Microbiota Optimization and Regulation · Phase 1 · active not recruiting
NCT06487832 — Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness · NA · recruiting
NCT06878781 — Postprandial Metabolome and Metabolic Flexibility · NA · recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04300049 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 21 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04300049.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing